Observational study suggests Apixaban for AF is associated with a lower risk of GI bleeding vs. other DOACs.

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)

News Release: Best blood thinner for minimizing bleeding risk identified – University College London

Commentary: GI Bleeding Lower With Apixaban Versus Other DOACs in A-Fib – HealthDay